The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2024 | Five-year post-approval updates: tagraxofusp in the treatment of BPDCN
Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a recently published five-year post-approval review outlining the role of tagraxofusp in the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). Dr Pemmaraju highlights that the drug has remained highly effective and exhibited no new safety signals since its approval, with advances being made in managing capillary leak syndrome (CLS). This interview took place at the 1st Annual MPN Workshop of the Carolinas in Asheville, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: ClearView Healthcare Partners, Imedex, Protagonist Therapeutics Inc., EUSA Pharma, Curio Science, CareDx, Harborside Press, Dava Oncology, CancerNet, Aplastic Anemia & MDS International Foundation, Pacylex, Patient Power, Menarini Group, Astellas, BMS, PeerView Institute for Medical Education, Stemline, Medscape, OncLive, Physician Education Resource (PER), Celgene, PharmaEssentia, Novartis Pharmaceuticals:, Magdalen Medical Publishing, Neopharm, Intellisphere, Blueprint, Cimeio Therapeutics AG, ImmunoGen, CTI BioPharma, Incyte, Aptitude Health, AbbVie, Bristol Myers Squibb Pharmaceuticals; Membership on Board of Directors/Advisory Committees: ClearView Healthcare Partners, Imedex, Protagonist Therapeutics Inc., EUSA Pharma, Curio Science, Dan’s House of Hope, CareDx, Harborside Press, Dava Oncology, CancerNet, Aplastic Anemia & MDS International Foundation, Pacylex, Patient Power, Menarini Group, Astellas, BMS, PeerView Institute for Medical Education, Stemline, Medscape, OncLive, Physician Education Resource (PER), Celgene, PharmaEssentia, Novartis Pharmaceuticals:, Magdalen Medical Publishing, Neopharm, Intellisphere, Blueprint, Cimeio Therapeutics AG, ImmunoGen, CTI BioPharma, Incyte, Aptitude Health, AbbVie, Bristol Myers Squibb Pharmaceuticals; Speakers Bureau: ClearView Healthcare Partners, Imedex, EUSA Pharma, Curio Science, CareDx, Harborside Press, Dava Oncology, CancerNet, Aplastic Anemia & MDS International Foundation, Pacylex, Patient Power, Menarini Group, Astellas, BMS, PeerView Institute for Medical Education, Medscape, OncLive, Physician Education Resource (PER), Celgene, PharmaEssentia, Novartis Pharmaceuticals, Magdalen Medical Publishing, Neopharm, Intellisphere, Blueprint, Cimeio Therapeutics AG, ImmunoGen, CTI BioPharma, Incyte, Aptitude Health, AbbVie, Bristol Myers Squibb Pharmaceuticals; Research Funding: United States Department of Defense (DOD), National Institute of Health/National Cancer Institute (NIH/NCI); Licenses: Karger Publishers; Leadership role on ASH Committee on Communications and ASCO Cancer.Net Editorial Board.
